NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Third Arc Bio

Third Arc Bio

Private
PennsylvaniaHealthcare & Life Scienceshttps://thirdarcbio.com/

Last Round

Series A

Extension

Feb 4, 2026

Total Funding Raised

$249M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Third Arc Bio is a biotechnology company that develops multifunctional antibodies designed to precisely activate or inhibit T cells for the treatment of solid tumors, inflammation, and immunological diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

T cell engagersmasked antibodybiotech startuponcology therapeuticsimmunologyCD3drug discoveryantibody engineeringbiopharmatherapeutic indexclinical stage biotechcomputational biologydrug pipelinebiotech funding

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Third Arc Bio Comps

Public and private peers based on sector, stage, and business model.

Third Arc Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Third Arc Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionFeb 4, 2026
Series AJul 23, 2024

Key People

Founding team and executive leadership

Sanjaya Singh

Chief Scientific Officer And Founder

Founding Team

Joseph Erhardt

Chief Operating Officer

Executive Team

Third Arc Bio Investors

Notable investors and investment history

Third Arc Bio investors
InvestorRounds
Andreessen HorowitzSeries A Extension
Janus Henderson GroupSeries A
Aberdeen Group plcSeries A Extension, Series A
Omega FundsSeries A, Seed, Series A Extension
Hillhouse InvestmentSeries A Extension, Series A
abrdn Inc.Series A, Series A Extension
Cormorant Asset ManagementSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 4, 2026

    $52M raised in Series A Extension round.

Third Arc Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Third Arc Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Third Arc Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersPennsylvania
Employee Range42
Year Founded2022
Last FundingFeb 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.